pf-04971729 and remogliflozin-etabonate

pf-04971729 has been researched along with remogliflozin-etabonate* in 1 studies

Reviews

1 review(s) available for pf-04971729 and remogliflozin-etabonate

Article	Year
Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica; the fate of foreign compounds in biological systems, 2017, Volume: 47, Issue:11 1. Several sodium-glucose cotransporter-2 (SGLT-2) inhibitors are in clinical use for the management of type 2 diabetes. The objectives of the current review were: (a) to provide a comparative pharmacokinetics including absorption, distribution, metabolism and excretory (ADME) profiles of three SGLT-2 inhibitors namely: sergliflozin, remogliflozin and ertugliflozin; (b) to provide some perspectives on possible developmental issues. 2. Based on the half-life (t Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Glucosides; Half-Life; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2	2017

Article

Year

Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.

Xenobiotica; the fate of foreign compounds in biological systems, 2017, Volume: 47, Issue:11

1. Several sodium-glucose cotransporter-2 (SGLT-2) inhibitors are in clinical use for the management of type 2 diabetes. The objectives of the current review were: (a) to provide a comparative pharmacokinetics including absorption, distribution, metabolism and excretory (ADME) profiles of three SGLT-2 inhibitors namely: sergliflozin, remogliflozin and ertugliflozin; (b) to provide some perspectives on possible developmental issues. 2. Based on the half-life (t

Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Glucosides; Half-Life; Humans; Hypoglycemic Agents; Pyrazoles; Sodium-Glucose Transporter 2

2017